FDA Grants Abiraterone Acetate ANDA208371 Approval Status
The FDA has granted application ANDA208371 for Abiraterone Acetate a status of Approved Pending (AP) under a supplemental submission.
Therapeutic Area
Therapeutic area intelligence for Hormonal Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.